Loading... Please wait...

Add to Wish List

Click the button below to add the Optimized Irvingia with Phase 3™ Calorie Control Complex to your wish list.

You Recently Viewed...

Our Newsletter


Optimized Irvingia with Phase 3™ Calorie Control Complex ™

  • Image 1
Price:
$56.00
SKU:
LE01492
Availability:
Usually ships within 24 hours
Shipping:
Calculated at checkout
Minimum Purchase:
1 unit(s)
Quantity:


Product Description

Optimized Irvingia with Phase 3™ Calorie Control Complex

 120 vegetarian capsules

 

The Optimized Irvingia with Phase 3™ Calorie Control Complex formulation provides a combination of natural compounds that combat age-related fat accumulation via the following eight distinct mechanisms:

  1. Delaying digestion and absorption of sucrose.
  2. Enhancing resting energy expenditure at the cellular level.
  3. Slowing the absorption of dietary fat from the intestines.
  4. Moderating alpha-amylase enzyme activity to reduce the absorption of carbohydrates into the bloodstream.
  5. Reducing alpha-glucosidase enzyme activity to further slow the absorption of starches and sugars into the bloodstream.
  6. Supporting leptin sensitivity to stimulate lipolysis.
  7. Supporting youthful levels of adiponectin to help maintain healthy insulin sensitivity.
  8. Moderating glycerol-3-phosphate dehydrogenase enzyme activity to reduce the amount of ingested starches that are converted to triglycerides and stored as fat.

Phase 3™ Sucrase Modulator

A study in the Journal of Science concluded that in primates a calorie-restricted diet can delay disease onset and age-related mortality.45 While Life Extension customers understand the benefits of calorie restriction, that doesn’t make it any easier to cut back on one of the major calorie culprits in the American diet: refined sugar.

Sucrase is the name given to a number of enzymes that catalyze the hydrolysis of sucrose to fructose and glucose in the small intestine for absorption into the bloodstream. Phase 3™ is a patented compound that functions as a beneficial sucrase modulator. It contains L-Arabinose, a natural substance found in plants that reduces the number of absorbed calories from sugar. Phase 3™ can help support healthy insulin metabolism and blood sugar levels in those already within normal range. Phase 3™ is just one ingredient in Optimized Irvingia.

Green Tea Phytosome Cellular Energy Enhancer

The ability of green tea extracts to inhibit the breakdown and absorption of dietary fat has been the subject of research studies across the globe. Mounting scientific research has documented the metabolic effects of green tea polyphenols. A proprietary phytosome complex has shown an ability to increase the absorption of green tea polyphenols into the bloodstream better than conventional tea extracts, resulting in peak plasma levels of the critical green tea polyphenol epigallocatechin-3-gallate.29

Participants in a human clinical trial showed an average weight loss of 30 pounds and a 10% reduction in waist circumference in 90 days when 300 mg/day of this new green tea phytosome was taken in conjunction with a reduced-calorie diet.46 The placebo group that followed the same reduced-calorie diet lost only 9.9 pounds on average and only 5% of their waist size. Optimized Irvingia contains the exact same green tea phytosome as was used in this study.

The Alpha-Amylase Enzyme

Aging reduces our ability to utilize the carbohydrates (and fats) that constitute what most would consider part of a healthy diet. The result is that as we grow older, our bloodstreams become chronically bloated with glucose and triglycerides in direct contrast to the youthful metabolic profile we have in our younger years. Emerging scientific research suggests that the alpha-amylase enzyme plays an undesirable role in the digestion of dietary carbohydrates and subsequent absorption of calories from starch and sugar.

A natural bean extract (Phaseolus vulgaris) moderates alpha-amylase activity. In a human trial in which all overweight participants were placed on a 2,000–2,200-calorie, carbohydrate-rich diet, those taking Phaseolus vulgaris lost 6.5 pounds and 1.2 inches in waist size in only 30 days compared with 0.8 pounds and 0.2 inches in the placebo group.47 Optimized Irvingia contains the identical Phaseolus vulgaris used in this study.

The Alpha-Glucosidase Enzyme

Another intestinal enzyme that enables carbohydrate absorption is alpha-glucosidase. A patented seaweed extract (InSea2™) has demonstrated the ability to help maintain healthy levels of both alpha-glucosidase and alpha-amylase. When given to laboratory animals, this seaweed extract reduced after-meal (postprandial) glucose elevations by up to 90% compared with non-supplemented animals.48

Remember, young healthy individuals rapidly convert ingested fats and sugars into energy. Age-related changes decrease our metabolic capacity to efficiently utilize dietary fats and sugars. It is thus paramount for aging people to reduce their absorption of excess calories. By taking nutrients before each meal that reduce the activity of carbohydrate and fat digesting enzymes, the calorie burden is significantly reduced. Optimized Irvingia provides the same InSea2™ extract used in laboratory studies.

Leptin Sensitivity

Fat cells (adipocytes) secrete a hormone called leptin that tells our brain we have eaten enough. Leptin can also facilitate the breakdown of stored triglycerides in our adipocytes via the process of lipolysis. Heavy individuals have startlingly high blood levels of leptin, indicating that their cells have become resistant to the leptin that is supposed to prevent them from putting on so many fat pounds.

An extract from an African mango called Irvingia gabonensishas been shown to help support leptin sensitivity in overweight people. In a recently published study,irvingia demonstrated beneficial effects upon leptin blood levels, followed by weight loss and inches off the waistline.49 In addition tosupporting healthy leptin sensitivity, irvingia has demonstrated the following beneficial effects on key aspects of metabolism:

  • Glycerol-3-phosphate dehydrogenase is an enzyme involved in the complex biochemical process that converts ingested starch and sugar calories to stored body fat. Irvingia has been shown in studies involving fat cells to reduce the activity of glycerol-3-phosphate dehydrogenase,50 which may help reduce the impact of starch and sugar calories on body fat.

  • Scientific research on fat cells suggests that irvingia has alpha-amylase-inhibiting properties51 (like InSea2™ and Phaseolus vulgaris) which can help support a slowing of the rate of carbohydrate absorption from the intestines and a reduction of the caloric impact of starchy and sugary foods.52

  • Adiponectin is a hormone involved in helping to maintain insulin sensitivity on the membranes of energy-producing cells. Big fat cells produce less adiponectin, and overweight people need to be especially concerned about maintaining healthy levels of adiponectin to support insulin sensitivity and metabolic fitness. Scientific data suggests that irvingia helps support healthy adiponectin levels.50

Optimized Irvingia with Phase 3™ Calorie Control Complex is indeed an innovative multi-modal approach to weight loss with an additional benefit. By helping to slow the absorption of starchy food or sugars, it reduces their caloric impact. And according to a recent mammalian study, those following a calorie-restricted diet were shown to significantly reduce the risk of mortality from age-related causes.45 This suggests that regular supplementation with this or any irvingia formulation may help provide anti-aging benefits similar to those found in this recent study.

This supplement should be taken in conjunction with a healthy diet and regular exercise program. Results may vary.

Supplement Facts

Serving Size 2 capsules

Servings Per Container 60

Amount Per Serving

Iodine (typical value naturally occurring from Ascophyllum nodosum and Fucus vesiculosus)

37.5 mcg

Chromium (as Chromium GlycoProtein Matrix)

100 mcg

Integra-Lean® African Mango (Irvingia gabonensis) proprietary extract (seed)

150 mg

Calorie Control Complex providing:

 

InSea2 [proprietary composition of demineralized polyphenols from brown seaweeds Kelp (Ascophyllum nodosum) and Bladderwrack (Fucus vesiculosus)]

125 mg

TeaSlender™ Green Tea Phytosome Green Tea (Camellia sinensis) Phytosome decaffeinated extract (leaf) containing standardized green tea extract bound to phosphatidylcholine (from lecithin)

150 mg

Phase 2® Phaseolus vulgaris white kidney (bean) extract

445 mg

Phase 3™ Sucrase Inhibitor L-Arabinose and Chromium GlycoProtein Matrix (supplying 475 mg L-arabinose and 100 mcg chromium in a food bound state)

550 mg

Other ingredients: vegetable cellulose (capsule), stearic acid, silica, vegetable stearate.

Contains soybeans. Contains yeast and corn. This product contains NO milk, egg, fish, peanuts, crustacean shellfish (lobster, crab, shrimp), tree nuts, wheat, gluten or rice. Contains NO artificial sweeteners, flavors, colors, or preservatives.

Integra-Lean® Irvingia is protected by U.S. Patent No. 7,537,790. Other patents pending InSea2™ is a trademark of innoVactiv™ Phase 2® and Phase 3™ are used under license.

Dosage and Use
 

Take two capsules twice daily 15 minutes before meals.

 

Best if taken before meals containing carbohydrates or starches, or as recommended by a healthcare practitioner.

Caution

Because this product may lower blood glucose, consult your healthcare provider before taking this product if you are taking blood glucose lowering medication.

Please Note

This product is designed to target several critical factors involved in age-related weight gain. Those who ingest more calories than what their body has the metabolic capacity to utilize will not see results. This is because some people are ingesting so many excess calories that no matter how much their metabolic rate is increased, or how much improvement occurs in their post-meal blood sugar and serum triglyceride levels, or how much youthful insulin sensitivity and other body fat-regulating systems are restored, they are overwhelming the metabolic capacity to utilize these calories. This will result in excess calories being stored in adipocytes. One cannot consume limitless calories and expect to shed fat pounds by taking drugs, nutrients, and/or hormones that demonstrate weight-loss effects in clinical studies.

Note

Due to license restrictions this product cannot be sold in Korea or France.

Warnings

warnings.png

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

1. Gerontology. 2006;52(2):69-75.   2. J Clin Invest. 1997 Sep 1;100(5):1166-73.   3. Pol Merkur Lekarski. 2005 Nov;19(113):634-7.   4. Med Hypotheses. 2001 Jun;56(6):702-8.   5. J Clin Endocrinol Metab. 1985 Sep;61(3):564-70.   6. Med Hypotheses. 2008;70(2):358-60.   7. Horm Metab Res. 2000 Nov-Dec;32(11-12):526-36.   8. Growth Horm IGF Res. 2002 Jun;12(3):147-61.   9. J Endocrinol Invest. 2005;28(3  Suppl):85-93.   10. Eur J Endocrinol. 2004  Jul;151(1):1-14.   11. Saudi Med J. 2003  Aug;24(8):837-41.   12. J Nutr Health Aging. 2002;6(2):123-6.   13. Metabolism. 1991 Feb;40(2):187-90.   14. J Endocrinol. 1996 Sep;150  Suppl:S155-S164.   15. Int J Obes Relat Metab Disord. 1992  Dec;16(12):991-7.   16. Metabolism. 1991  Jan;40(1):101-4.   17. Metabolism. 1990  Sep;39(9):897-901.   18. Drugs Aging. 2008;25(5):357-69.   19. Andrologia. 2008 Aug;40(4):259-64.   20. Int J Obes Relat Metab Disord. 2000  Apr;24(4):485-91.   21. Int J Obes Relat Metab Disord. 1994  Oct;18(10):659-64.   22. Int J Obes Relat Metab Disord. 2003  Sep;27(9):1044-51.   23. Horm Metab Res. 2002  Oct;34(10):583-8.   24. Menopause. 2000  Nov-Dec;7(6):395-401.   25. Metabolism. 1994  Mar;43(3):390-5.   26. Endocrinology. 2007 Dec;148(12):5667-79.   27. Obes Res. 2005  Apr;13(4):717-28.   28. Progress  in Obesity Research. John Libbey &  Company, Ltd., 1990:507-14.   29. Eur J Pharmaceut Biopharmaceut. 2009;72:453-62.   30. Agr Biol Chem. 1975;39(2):301-12.   31. U.S.  Patent 3,856,945   32. U.S.  Patent 3,928,322   33. U.S.  Patent 3,973,008   34. U.S.  Patent 3,767,424   35. Int J  Obes. 1984;8(4):289-93.   36. Curr  Ther Res. 1989 Nov;46(5):908-12.   37. Altern  Med Rev. 2004 Mar;9(1):63-9.   38. Altern  Ther Health Med. 2007 Jul-Aug;13(4):32-7.   39. Int J  Med Sci. 2007 Jan 24;4(1):45-52.   40. Ann  Nutr Metab. 1993; 37(1):14-23.   41. Lipids  Health Dis. 2009 Mar 2;8:7.   42. Lipids  Health Dis. 2008 Mar 31;7:12.   43. Physiol Behav. 2010 Apr 26;100(1):42-6.        44. Integr  Nutr. 2008;11(2):1-14.   45. Science. 2009 Jul 10;325(5937):201-4.   46. Integr Nutr. 2008;11(2):1-14.   47. Int J Med Sci. 2007;4:45-52.   48. Tecnhincal Note: InSea2 In Vivo  Technical Report   49. Lipids Health  Dis. 2009 Mar 2;8:7.   50. Lipids Health  Dis. 2008 Nov 13;7:44.   51. Ann Nutr Metab.  1993;37(1):14-23.   52. Lipids Health  Dis. 2008 Mar 31;7:12.   53. Submitted for  publication, 2009.   54.  http://shimizuchemical.co.jp/eng/propol/index.html. Accessed July 28, 2010.   55. Eur J Pharmaceut  Biopharmaceut. 2009;72:453-62.   56. Agr Biol Chem. 1975;39(2):301-12.   57.  U.S. Patent 3,856,945   58.  U.S. Patent 3,928,322   59.  U.S. Patent 3,973,008   60.  U.S. Patent 3,767,424   61. Progress in Obesity Research. John  Libbey & Company, Ltd., 1990:507-14.   62. Int J Obes.  1984;8(4):289-93.   63. Curr Ther Res.  1989 Nov;46(5):908-12.   64. Eur J Clin Nutr. 2006;60:18-24.   65. Biochem Biophys Res Commun. 2005 Jul  1;332(2):392-7.   66. Int J Mol Med. 2006  Jul;18(1):147-52.   67. Submitted for publication. 2008.   68. Submitted for publication. 2008.   69. Diabetes Obes Metab. 2010  Jan;12(1):72-81.   70. Br J Nutr. 2009  Jul;102(1):54-9.   71. JAMA. 2006 Apr 5;295(13):1539-48.   72. Proc Natl Acad Sci U S A. 2006 May  16;103(20):7901-5.   73. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):679-87.   74. Lipids Health Dis. 2008 Mar 20;7:10.   75. Food in Medieval Times. Greenwood Publishing;  2004.   76. Saffron (Crocus sativus) Production  and Processing.  Science Publishers; 2006.   77. Hum Reprod. 1997  Jun;12(6):1142-51.   78. BMC Complement Altern Med.  2004 Sep 2;4:12.   79. J Ethnopharmacol. 2005 Feb  28;97(2):281-4.   80. Prog  Neuropsychopharmacol Biol Psychiatry. 2007  Mar  30;31(2):439-42.   81. Nutraveris; 2006.  Unpublished study.   82. Nutr  Res. 2010 May;30(5):305-13.   83. JAMA. 2004 Nov 10;292(18):2243-8.   84. Curr Ther Res; 2002;63(4):263-72.   85. Arch Biochem Biophys. 1997 May  1;341(1):122-8.   86. Curr Therap Res. 2000;61(7):435-42.   87. J Nutr Biochem. 2007  Sep;18(9):629-34.   88. Proc Natl Acad Sci U S A. 1995 Jul  3;92(14):6617-9.   89. Steroids. 2000 Mar;65(3):124-9.   90. Altern Ther Health Med. 2005;11(6):30-4.   91. J Am Coll Nutr. 2003  Feb;22(1):36-42.    92. Nutr Hosp. 2004  Jan-Feb;19(1):45-50.   93. Med Sci Sports Exerc. 2004  May;36(5):814-20.   94. Eur J Clin Nutr. 2003 Apr;57(4):595-603.   95. Br J Nutr. 2002 Sep;88(3):243-51.   96. Lipids. 2001 Mar;36(3):221-7.   97. Am J Clin Nutr. 2004 Jun;79(6):1118-25.   98. J Int Med Res. 2001 Sep-Oct;29(5):392-6.   99. Int J Obes Relat Metab Disord. 2001  Aug;25(8):1129-35.   100. Lipids. 2001 Aug;36(8):773-81.   101. J Nutr. 2000 Dec;130(12):2943-8.   102. J Nutr. 2007 May;137(5):1188-93.,   103. Br J Nutr. 2007  May;97(5):1001-11.,   104. Br J Nutr. 2007 Mar;97(3):550-60.,   105. Br J Nutr. 2007 Feb;97(2):273-80.,   106. Int J Obes (Lond). 2007 Mar;31(3):481-7.   107. Am J Clin Nutr. 2007 May;85(5):1203-11.   108. Metabolism. 1999  Oct;48(10):1303-13.   109. Biosci Biotechnol Biochem. 2001  Nov;65(11):2535-41.   110. J Pharm Pharmacol. 1992 Sep;44(9):769-71.   111. Int J Obes Relat Metab Disord. 2002 Jun;26(6):870-2.   112. J Med. 2004;35(1-6):33-48.   113. Phytochemistry. 2007  Oct;68(20):2545-53.   114. J Agric Food Chem. 2003 Oct  22;51(22):6618-22.   115. J Nat Prod. 1982  Sep-Oct;45(5):590-99.   116. Food Chem Toxicol. 2003  Jun;41(6):875-83.   117. J Toxicol Sci. 2002 Dec;27 Suppl  1:1-8.   118. Food Chem Toxicol. 2003 Mar;41(3):359-74.   119. Food Chem Toxicol. 2008 Jul;46 Suppl  7:S1-S10.   120. Metabolism. 2004  Jan;53(1):73-6.   121. Braz J Med Biol Res. 1986;19(6):771-4.   122. Metabolism. 2004 Jan;53(1):73-6.

Optimized Irvingia with Phase 3™ Calorie Control Complex

Optimized Irvingia with Phase 3™ Calorie Control Complex

 120 vegetarian capsules

 

The Optimized Irvingia with Phase 3™ Calorie Control Complex formulation provides a combination of natural compounds that combat age-related fat accumulation via the following eight distinct mechanisms:

  1. Delaying digestion and absorption of sucrose.
  2. Enhancing resting energy expenditure at the cellular level.
  3. Slowing the absorption of dietary fat from the intestines.
  4. Moderating alpha-amylase enzyme activity to reduce the absorption of carbohydrates into the bloodstream.
  5. Reducing alpha-glucosidase enzyme activity to further slow the absorption of starches and sugars into the bloodstream.
  6. Supporting leptin sensitivity to stimulate lipolysis.
  7. Supporting youthful levels of adiponectin to help maintain healthy insulin sensitivity.
  8. Moderating glycerol-3-phosphate dehydrogenase enzyme activity to reduce the amount of ingested starches that are converted to triglycerides and stored as fat.

Phase 3™ Sucrase Modulator

A study in the Journal of Science concluded that in primates a calorie-restricted diet can delay disease onset and age-related mortality.45 While Life Extension customers understand the benefits of calorie restriction, that doesn’t make it any easier to cut back on one of the major calorie culprits in the American diet: refined sugar.

Sucrase is the name given to a number of enzymes that catalyze the hydrolysis of sucrose to fructose and glucose in the small intestine for absorption into the bloodstream. Phase 3™ is a patented compound that functions as a beneficial sucrase modulator. It contains L-Arabinose, a natural substance found in plants that reduces the number of absorbed calories from sugar. Phase 3™ can help support healthy insulin metabolism and blood sugar levels in those already within normal range. Phase 3™ is just one ingredient in Optimized Irvingia.

Green Tea Phytosome Cellular Energy Enhancer

The ability of green tea extracts to inhibit the breakdown and absorption of dietary fat has been the subject of research studies across the globe. Mounting scientific research has documented the metabolic effects of green tea polyphenols. A proprietary phytosome complex has shown an ability to increase the absorption of green tea polyphenols into the bloodstream better than conventional tea extracts, resulting in peak plasma levels of the critical green tea polyphenol epigallocatechin-3-gallate.29

Participants in a human clinical trial showed an average weight loss of 30 pounds and a 10% reduction in waist circumference in 90 days when 300 mg/day of this new green tea phytosome was taken in conjunction with a reduced-calorie diet.46 The placebo group that followed the same reduced-calorie diet lost only 9.9 pounds on average and only 5% of their waist size. Optimized Irvingia contains the exact same green tea phytosome as was used in this study.

The Alpha-Amylase Enzyme

Aging reduces our ability to utilize the carbohydrates (and fats) that constitute what most would consider part of a healthy diet. The result is that as we grow older, our bloodstreams become chronically bloated with glucose and triglycerides in direct contrast to the youthful metabolic profile we have in our younger years. Emerging scientific research suggests that the alpha-amylase enzyme plays an undesirable role in the digestion of dietary carbohydrates and subsequent absorption of calories from starch and sugar.

A natural bean extract (Phaseolus vulgaris) moderates alpha-amylase activity. In a human trial in which all overweight participants were placed on a 2,000–2,200-calorie, carbohydrate-rich diet, those taking Phaseolus vulgaris lost 6.5 pounds and 1.2 inches in waist size in only 30 days compared with 0.8 pounds and 0.2 inches in the placebo group.47 Optimized Irvingia contains the identical Phaseolus vulgaris used in this study.

The Alpha-Glucosidase Enzyme

Another intestinal enzyme that enables carbohydrate absorption is alpha-glucosidase. A patented seaweed extract (InSea2™) has demonstrated the ability to help maintain healthy levels of both alpha-glucosidase and alpha-amylase. When given to laboratory animals, this seaweed extract reduced after-meal (postprandial) glucose elevations by up to 90% compared with non-supplemented animals.48

Remember, young healthy individuals rapidly convert ingested fats and sugars into energy. Age-related changes decrease our metabolic capacity to efficiently utilize dietary fats and sugars. It is thus paramount for aging people to reduce their absorption of excess calories. By taking nutrients before each meal that reduce the activity of carbohydrate and fat digesting enzymes, the calorie burden is significantly reduced. Optimized Irvingia provides the same InSea2™ extract used in laboratory studies.

Leptin Sensitivity

Fat cells (adipocytes) secrete a hormone called leptin that tells our brain we have eaten enough. Leptin can also facilitate the breakdown of stored triglycerides in our adipocytes via the process of lipolysis. Heavy individuals have startlingly high blood levels of leptin, indicating that their cells have become resistant to the leptin that is supposed to prevent them from putting on so many fat pounds.

An extract from an African mango called Irvingia gabonensishas been shown to help support leptin sensitivity in overweight people. In a recently published study,irvingia demonstrated beneficial effects upon leptin blood levels, followed by weight loss and inches off the waistline.49 In addition tosupporting healthy leptin sensitivity, irvingia has demonstrated the following beneficial effects on key aspects of metabolism:

  • Glycerol-3-phosphate dehydrogenase is an enzyme involved in the complex biochemical process that converts ingested starch and sugar calories to stored body fat. Irvingia has been shown in studies involving fat cells to reduce the activity of glycerol-3-phosphate dehydrogenase,50 which may help reduce the impact of starch and sugar calories on body fat.

  • Scientific research on fat cells suggests that irvingia has alpha-amylase-inhibiting properties51 (like InSea2™ and Phaseolus vulgaris) which can help support a slowing of the rate of carbohydrate absorption from the intestines and a reduction of the caloric impact of starchy and sugary foods.52

  • Adiponectin is a hormone involved in helping to maintain insulin sensitivity on the membranes of energy-producing cells. Big fat cells produce less adiponectin, and overweight people need to be especially concerned about maintaining healthy levels of adiponectin to support insulin sensitivity and metabolic fitness. Scientific data suggests that irvingia helps support healthy adiponectin levels.50

Optimized Irvingia with Phase 3™ Calorie Control Complex is indeed an innovative multi-modal approach to weight loss with an additional benefit. By helping to slow the absorption of starchy food or sugars, it reduces their caloric impact. And according to a recent mammalian study, those following a calorie-restricted diet were shown to significantly reduce the risk of mortality from age-related causes.45 This suggests that regular supplementation with this or any irvingia formulation may help provide anti-aging benefits similar to those found in this recent study.

This supplement should be taken in conjunction with a healthy diet and regular exercise program. Results may vary.

Supplement Facts

Serving Size 2 capsules

Servings Per Container 60

Amount Per Serving

Iodine (typical value naturally occurring from Ascophyllum nodosum and Fucus vesiculosus)

37.5 mcg

Chromium (as Chromium GlycoProtein Matrix)

100 mcg

Integra-Lean® African Mango (Irvingia gabonensis) proprietary extract (seed)

150 mg

Calorie Control Complex providing:

 

InSea2 [proprietary composition of demineralized polyphenols from brown seaweeds Kelp (Ascophyllum nodosum) and Bladderwrack (Fucus vesiculosus)]

125 mg

TeaSlender™ Green Tea Phytosome Green Tea (Camellia sinensis) Phytosome decaffeinated extract (leaf) containing standardized green tea extract bound to phosphatidylcholine (from lecithin)

150 mg

Phase 2® Phaseolus vulgaris white kidney (bean) extract

445 mg

Phase 3™ Sucrase Inhibitor L-Arabinose and Chromium GlycoProtein Matrix (supplying 475 mg L-arabinose and 100 mcg chromium in a food bound state)

550 mg

Other ingredients: vegetable cellulose (capsule), stearic acid, silica, vegetable stearate.

Contains soybeans. Contains yeast and corn. This product contains NO milk, egg, fish, peanuts, crustacean shellfish (lobster, crab, shrimp), tree nuts, wheat, gluten or rice. Contains NO artificial sweeteners, flavors, colors, or preservatives.

Integra-Lean® Irvingia is protected by U.S. Patent No. 7,537,790. Other patents pending InSea2™ is a trademark of innoVactiv™ Phase 2® and Phase 3™ are used under license.

Dosage and Use
 

Take two capsules twice daily 15 minutes before meals.

 

Best if taken before meals containing carbohydrates or starches, or as recommended by a healthcare practitioner.

Caution

Because this product may lower blood glucose, consult your healthcare provider before taking this product if you are taking blood glucose lowering medication.

Please Note

This product is designed to target several critical factors involved in age-related weight gain. Those who ingest more calories than what their body has the metabolic capacity to utilize will not see results. This is because some people are ingesting so many excess calories that no matter how much their metabolic rate is increased, or how much improvement occurs in their post-meal blood sugar and serum triglyceride levels, or how much youthful insulin sensitivity and other body fat-regulating systems are restored, they are overwhelming the metabolic capacity to utilize these calories. This will result in excess calories being stored in adipocytes. One cannot consume limitless calories and expect to shed fat pounds by taking drugs, nutrients, and/or hormones that demonstrate weight-loss effects in clinical studies.

Note

Due to license restrictions this product cannot be sold in Korea or France.

Warnings

warnings.png

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

1. Gerontology. 2006;52(2):69-75.   2. J Clin Invest. 1997 Sep 1;100(5):1166-73.   3. Pol Merkur Lekarski. 2005 Nov;19(113):634-7.   4. Med Hypotheses. 2001 Jun;56(6):702-8.   5. J Clin Endocrinol Metab. 1985 Sep;61(3):564-70.   6. Med Hypotheses. 2008;70(2):358-60.   7. Horm Metab Res. 2000 Nov-Dec;32(11-12):526-36.   8. Growth Horm IGF Res. 2002 Jun;12(3):147-61.   9. J Endocrinol Invest. 2005;28(3  Suppl):85-93.   10. Eur J Endocrinol. 2004  Jul;151(1):1-14.   11. Saudi Med J. 2003  Aug;24(8):837-41.   12. J Nutr Health Aging. 2002;6(2):123-6.   13. Metabolism. 1991 Feb;40(2):187-90.   14. J Endocrinol. 1996 Sep;150  Suppl:S155-S164.   15. Int J Obes Relat Metab Disord. 1992  Dec;16(12):991-7.   16. Metabolism. 1991  Jan;40(1):101-4.   17. Metabolism. 1990  Sep;39(9):897-901.   18. Drugs Aging. 2008;25(5):357-69.   19. Andrologia. 2008 Aug;40(4):259-64.   20. Int J Obes Relat Metab Disord. 2000  Apr;24(4):485-91.   21. Int J Obes Relat Metab Disord. 1994  Oct;18(10):659-64.   22. Int J Obes Relat Metab Disord. 2003  Sep;27(9):1044-51.   23. Horm Metab Res. 2002  Oct;34(10):583-8.   24. Menopause. 2000  Nov-Dec;7(6):395-401.   25. Metabolism. 1994  Mar;43(3):390-5.   26. Endocrinology. 2007 Dec;148(12):5667-79.   27. Obes Res. 2005  Apr;13(4):717-28.   28. Progress  in Obesity Research. John Libbey &  Company, Ltd., 1990:507-14.   29. Eur J Pharmaceut Biopharmaceut. 2009;72:453-62.   30. Agr Biol Chem. 1975;39(2):301-12.   31. U.S.  Patent 3,856,945   32. U.S.  Patent 3,928,322   33. U.S.  Patent 3,973,008   34. U.S.  Patent 3,767,424   35. Int J  Obes. 1984;8(4):289-93.   36. Curr  Ther Res. 1989 Nov;46(5):908-12.   37. Altern  Med Rev. 2004 Mar;9(1):63-9.   38. Altern  Ther Health Med. 2007 Jul-Aug;13(4):32-7.   39. Int J  Med Sci. 2007 Jan 24;4(1):45-52.   40. Ann  Nutr Metab. 1993; 37(1):14-23.   41. Lipids  Health Dis. 2009 Mar 2;8:7.   42. Lipids  Health Dis. 2008 Mar 31;7:12.   43. Physiol Behav. 2010 Apr 26;100(1):42-6.        44. Integr  Nutr. 2008;11(2):1-14.   45. Science. 2009 Jul 10;325(5937):201-4.   46. Integr Nutr. 2008;11(2):1-14.   47. Int J Med Sci. 2007;4:45-52.   48. Tecnhincal Note: InSea2 In Vivo  Technical Report   49. Lipids Health  Dis. 2009 Mar 2;8:7.   50. Lipids Health  Dis. 2008 Nov 13;7:44.   51. Ann Nutr Metab.  1993;37(1):14-23.   52. Lipids Health  Dis. 2008 Mar 31;7:12.   53. Submitted for  publication, 2009.   54.  http://shimizuchemical.co.jp/eng/propol/index.html. Accessed July 28, 2010.   55. Eur J Pharmaceut  Biopharmaceut. 2009;72:453-62.   56. Agr Biol Chem. 1975;39(2):301-12.   57.  U.S. Patent 3,856,945   58.  U.S. Patent 3,928,322   59.  U.S. Patent 3,973,008   60.  U.S. Patent 3,767,424   61. Progress in Obesity Research. John  Libbey & Company, Ltd., 1990:507-14.   62. Int J Obes.  1984;8(4):289-93.   63. Curr Ther Res.  1989 Nov;46(5):908-12.   64. Eur J Clin Nutr. 2006;60:18-24.   65. Biochem Biophys Res Commun. 2005 Jul  1;332(2):392-7.   66. Int J Mol Med. 2006  Jul;18(1):147-52.   67. Submitted for publication. 2008.   68. Submitted for publication. 2008.   69. Diabetes Obes Metab. 2010  Jan;12(1):72-81.   70. Br J Nutr. 2009  Jul;102(1):54-9.   71. JAMA. 2006 Apr 5;295(13):1539-48.   72. Proc Natl Acad Sci U S A. 2006 May  16;103(20):7901-5.   73. Curr Opin Clin Nutr Metab Care. 2007 Nov;10(6):679-87.   74. Lipids Health Dis. 2008 Mar 20;7:10.   75. Food in Medieval Times. Greenwood Publishing;  2004.   76. Saffron (Crocus sativus) Production  and Processing.  Science Publishers; 2006.   77. Hum Reprod. 1997  Jun;12(6):1142-51.   78. BMC Complement Altern Med.  2004 Sep 2;4:12.   79. J Ethnopharmacol. 2005 Feb  28;97(2):281-4.   80. Prog  Neuropsychopharmacol Biol Psychiatry. 2007  Mar  30;31(2):439-42.   81. Nutraveris; 2006.  Unpublished study.   82. Nutr  Res. 2010 May;30(5):305-13.   83. JAMA. 2004 Nov 10;292(18):2243-8.   84. Curr Ther Res; 2002;63(4):263-72.   85. Arch Biochem Biophys. 1997 May  1;341(1):122-8.   86. Curr Therap Res. 2000;61(7):435-42.   87. J Nutr Biochem. 2007  Sep;18(9):629-34.   88. Proc Natl Acad Sci U S A. 1995 Jul  3;92(14):6617-9.   89. Steroids. 2000 Mar;65(3):124-9.   90. Altern Ther Health Med. 2005;11(6):30-4.   91. J Am Coll Nutr. 2003  Feb;22(1):36-42.    92. Nutr Hosp. 2004  Jan-Feb;19(1):45-50.   93. Med Sci Sports Exerc. 2004  May;36(5):814-20.   94. Eur J Clin Nutr. 2003 Apr;57(4):595-603.   95. Br J Nutr. 2002 Sep;88(3):243-51.   96. Lipids. 2001 Mar;36(3):221-7.   97. Am J Clin Nutr. 2004 Jun;79(6):1118-25.   98. J Int Med Res. 2001 Sep-Oct;29(5):392-6.   99. Int J Obes Relat Metab Disord. 2001  Aug;25(8):1129-35.   100. Lipids. 2001 Aug;36(8):773-81.   101. J Nutr. 2000 Dec;130(12):2943-8.   102. J Nutr. 2007 May;137(5):1188-93.,   103. Br J Nutr. 2007  May;97(5):1001-11.,   104. Br J Nutr. 2007 Mar;97(3):550-60.,   105. Br J Nutr. 2007 Feb;97(2):273-80.,   106. Int J Obes (Lond). 2007 Mar;31(3):481-7.   107. Am J Clin Nutr. 2007 May;85(5):1203-11.   108. Metabolism. 1999  Oct;48(10):1303-13.   109. Biosci Biotechnol Biochem. 2001  Nov;65(11):2535-41.   110. J Pharm Pharmacol. 1992 Sep;44(9):769-71.   111. Int J Obes Relat Metab Disord. 2002 Jun;26(6):870-2.   112. J Med. 2004;35(1-6):33-48.   113. Phytochemistry. 2007  Oct;68(20):2545-53.   114. J Agric Food Chem. 2003 Oct  22;51(22):6618-22.   115. J Nat Prod. 1982  Sep-Oct;45(5):590-99.   116. Food Chem Toxicol. 2003  Jun;41(6):875-83.   117. J Toxicol Sci. 2002 Dec;27 Suppl  1:1-8.   118. Food Chem Toxicol. 2003 Mar;41(3):359-74.   119. Food Chem Toxicol. 2008 Jul;46 Suppl  7:S1-S10.   120. Metabolism. 2004  Jan;53(1):73-6.   121. Braz J Med Biol Res. 1986;19(6):771-4.   122. Metabolism. 2004 Jan;53(1):73-6.

$56.00

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!